Tandem Diabetes Care, Inc.’s (TNDM) growth is backed by its impressive range of new products. The flourishing diabetes market provides a favorable opportunity for the company’s growth. However, concerns loom over Tandem Diabetes’ substantial reliance on insulin pumps and the adverse impact of macroeconomic challenges.In the past year, this Zacks Rank #3 (Hold) company has surged 56.2% compared with 10.9% growth of the industry and a 24.9% rise of the S&P 500 composite.The renowned medical device company has ...